DK104193C - Fremgangsmåde til stabilisering af labile, antigene virusmaterialer. - Google Patents

Fremgangsmåde til stabilisering af labile, antigene virusmaterialer.

Info

Publication number
DK104193C
DK104193C DK368963AA DK368963A DK104193C DK 104193 C DK104193 C DK 104193C DK 368963A A DK368963A A DK 368963AA DK 368963 A DK368963 A DK 368963A DK 104193 C DK104193 C DK 104193C
Authority
DK
Denmark
Prior art keywords
viral materials
antigenic viral
stabilizing labile
labile
stabilizing
Prior art date
Application number
DK368963AA
Other languages
English (en)
Original Assignee
Parke Davis & Company A Corp O
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Parke Davis & Company A Corp O filed Critical Parke Davis & Company A Corp O
Application granted granted Critical
Publication of DK104193C publication Critical patent/DK104193C/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A61K39/165—Mumps or measles virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A61K39/13—Poliovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A61K39/285—Vaccinia virus or variola virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
DK368963AA 1962-08-16 1963-08-01 Fremgangsmåde til stabilisering af labile, antigene virusmaterialer. DK104193C (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US217293A US3186908A (en) 1962-08-16 1962-08-16 Calcium lactobionate stabilization of labile antigenic virus vaccine materials

Publications (1)

Publication Number Publication Date
DK104193C true DK104193C (da) 1966-04-18

Family

ID=22810442

Family Applications (1)

Application Number Title Priority Date Filing Date
DK368963AA DK104193C (da) 1962-08-16 1963-08-01 Fremgangsmåde til stabilisering af labile, antigene virusmaterialer.

Country Status (10)

Country Link
US (1) US3186908A (da)
BR (1) BR6351350D0 (da)
CH (1) CH412201A (da)
DE (1) DE1227615B (da)
DK (1) DK104193C (da)
ES (1) ES290512A1 (da)
FI (1) FI40108C (da)
FR (1) FR1594506A (da)
GB (1) GB1049386A (da)
SE (1) SE314774B (da)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4380582A (en) * 1965-07-09 1983-04-19 The United States Of America As Represented By The Secretary Of The Army Preparation of dry variola virus
DE1617457A1 (de) * 1966-12-16 1972-04-20 Erba Carlo Spa Verfahren zur Stabilisierung von Zubereitungen interferierender Virusprodukte
FR2076787A5 (en) * 1970-01-28 1971-10-15 Merieux Inst Lyophilisation stabiliser - for viruses contg potassium phosphate lactose and albumin
JPS5716823A (en) * 1980-07-03 1982-01-28 Green Cross Corp:The Live mumps vaccine pharmaceutical and stabilizing method
FR2505657A1 (fr) * 1981-05-13 1982-11-19 Pasteur Institut Perfectionnements apportes aux agents de stabilisation de virus vivants pour la preparation de vaccins, et vaccins stabilises contenant lesdits agents de stabilisation
JPS59163313A (ja) * 1983-03-09 1984-09-14 Teijin Ltd 経鼻投与用ペプチドホルモン類組成物
GB0218821D0 (en) * 2002-08-13 2002-09-18 Glaxosmithkline Biolog Sa Novel compositions
CN116115766B (zh) * 2023-02-06 2024-04-09 广东永顺生物制药股份有限公司 一种活疫苗耐热冻干保护剂及其制备方法与应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA603832A (en) * 1960-08-23 J. Scott William Method and means for the dried storage of micro-organisms
US2186975A (en) * 1933-04-10 1940-01-16 Horace S Isbell Crystalline calcium lactobionate calcium bromide and process for making the same
GB716920A (en) * 1951-07-31 1954-10-20 Andre Jean Pierre Joseph Thoma A process for the mass production and treatment of pathogenic viruses and substances which accompany them
US2879202A (en) * 1954-11-05 1959-03-24 American Cyanamid Co Stabilization of live viral vaccines by hexahydric alcohols
US2912361A (en) * 1956-11-28 1959-11-10 Sterling Drug Inc Canine distemper vaccine and its preparation
US2946724A (en) * 1957-05-29 1960-07-26 American Cyanamid Co Stable poliomyelitis live virus vaccine
GB899011A (en) * 1958-03-14 1962-06-20 Upjohn Co Rubeola vaccine and process
US3031378A (en) * 1959-05-30 1962-04-24 Ishidate Morizo Method of inactivating viruses
GB900115A (en) * 1960-06-15 1962-07-04 Armour & Co Improvements in or relating to trypsin solutions

Also Published As

Publication number Publication date
SE314774B (da) 1969-09-15
CH412201A (fr) 1966-04-30
FI40108B (da) 1968-06-28
FI40108C (fi) 1968-10-10
FR1594506A (da) 1970-06-08
US3186908A (en) 1965-06-01
ES290512A1 (es) 1963-11-16
GB1049386A (en) 1966-11-23
DE1227615B (de) 1966-10-27
BR6351350D0 (pt) 1973-08-02

Similar Documents

Publication Publication Date Title
DK127415B (da) Fremgangsmåde til fremstilling af α-benzyl-β,β-dialkoxypropionitriler.
DK108985C (da) Fremgangsmåde til fremstilling af mæslingevaccine indeholdende levende, svækket mæslingevirus.
DK106988C (da) Fremgangsmåde til imprægnering af træ.
DK104193C (da) Fremgangsmåde til stabilisering af labile, antigene virusmaterialer.
DK121316B (da) Fremgangsmåde til afsvækkelse af levende mæslingevirus.
DK106185C (da) Fremgangsmåde til fremstilling af 17α-acyloxy-4,6-pregnadien-20-oner.
DK120752B (da) Fremgangsmåde til fremstilling af 5-aryl-3H-1,4-benzodiazepin-4-oxider.
DK108227C (da) Fremgangsmåde til fremstilling af 3-carbonhydridoxy-17α-halogenethinyl-19-nor-3,5-androstadien-17β-oler.
DK116056B (da) Fremgangsmåde til fremstilling af 13-alkyl-gona-4,9-dien-3-oner eller deres D-homo-analoge.
DK106328C (da) Fremgangsmåde til fremstilling af 17α-alkoxy-16-methylen-3,20-diketopregnanderivater.
DK124753B (da) Analogifremgangsmåde til fremstilling af 13-alkyl-gonen-3,17-dioler.
DK103188C (da) Fremgangsmåde til fremstilling af endometylen-2,3-dimetylhexahydropyridazin eller kvaternære ammoniumforbindelser deraf.
DK119354B (da) Fremgangsmåde til fremstilling af 3-sulfamoyl-5-tert.-aminopropyliden-5H-dibenzo-[a,d]-cycloheptener.
DK114204B (da) Fremgangsmåde til fremstilling af carboxamidoalkyl-1,3-benzoxaziner.
DK105983C (da) Fremgangsmåde til fremstilling af 2-alkoxy-5-aryl-3H-1,4-benzodiazepin-4-oxider.
DK121297B (da) Fremgangsmåde til fremstilling af 19-hydroxyandrost-4-en-3,17-dion.
DK114902B (da) Fremgangsmåde til fremstilling af O,S-disubstituerede thiol-thiaminderivater.
DK111700B (da) Fremgangsmåde til udvinding af 3β-hydroxy-14β, 15β-epoxy-5β-bufa-20,22-dienolid.
DK109324C (da) Fremgangsmåde til fremstilling af 1-brom-chlor-2,2-difluorpropan.
DK105036C (da) Fremgangsmåde til fremstilling af 7-desacetylamino-11,12-dihydrocolchicein.
DK98328C (da) Fremgangsmåde til fremstilling af 3α-acyloxy-11-oxo-20,20-bis-phosphatomethyl-21-hydroxy-5β-pregnaner.
DK96738C (da) Fremgangsmåde til fremstilling af 3α-acyloxy-11-oxo-20,20-bis-(hydroxymethyl)-21-hydroxy-5β-pregnaner.
DK106330C (da) Fremgangsmåde til fremstilling af 16-halogenmethylen-17α-hydroxy-3,20-diketo-4,6-pregnadienderivater.
DK101588C (da) Fremgangsmåde til fremstilling af 2-chlor-3,5-dialkoxy-phenoler.
DK99633C (da) Fremgangsmåde til fremstilling af 6α-methyl-16-methylen-17α-hydroxy-1,4-pregnadienforbindelser.